Storage stable formulations of sulfated glycosaminoglycans and fragments derived therefrom for the treatment of pain and other medical conditions
One aspect of the present application relates to a storage stable pharmaceutical composition comprising a sulfated glycosaminoglycan having an average molecular weight ranging from 3,000 to 15,000 Daltons, and a pharmaceutical carrier, where the pharmaceutical carrier is mixed with the sulfated glycosaminoglycan, as well as this composition's use in a method of treating a subject for a medically observable improvement. Another aspect of the present application relates to a process for producing a storage stable purified sulfated glycosaminoglycan.
1 . A storage stable sulfated glycosaminoglycan having an average molecular weight ranging from 3,000 to 15,000 Daltons, wherein said sulfated glycosaminoglycan includes no more than 10 wt % of carbohydrates or other contaminants with a molecular weight below 1,000 Daltons.
2 . The storage stable sulfated glycosaminoglycan of claim 1 , wherein said sulfated glycosaminoglycan has an average molecular weight ranging from 7,000 to 9,500 Daltons.
3 . The storage stable sulfated glycosaminoglycan of claim 1 , wherein said sulfated glycosaminoglycan is selected from the group consisting of mucopolysaccharide polysulfate, polysulfated glycosaminoglycan, and combinations thereof.
4 . The storage stable sulfated glycosaminoglycan of claim 1 , wherein said sulfated glycosaminoglycan comprises repeating disaccharide units of N-acetylgalactosamine and glucuronic acid.
5 . The storage stable sulfated glycosaminoglycan of claim 1 , wherein said sulfated glycosaminoglycan has a sulfate to carboxylate ratio between 3:1 and 4:1.
6 . The storage stable sulfated glycosaminoglycan of claim 1 , wherein said sulfated glycosaminoglycan comprises less than 5 wt % of chondroitin sulfate.
7 . The storage stable sulfated glycosaminoglycan of claim 1 , wherein said sulfated glycosaminoglycan is prepared from chondroitin sulfate.
8 . The storage stable sulfated glycosaminoglycan of claim 3 , wherein said sulfated glycosaminoglycan comprises mucopolysaccharide polysulfate.
9 . The storage stable sulfated glycosaminoglycan of claim 1 , wherein said sulfated glycosaminoglycan contains less than 5,000 ppm of acetic acid.
10 . The storage stable sulfated glycosaminoglycan of claim 1 , wherein said sulfated glycosaminoglycan contains less than 5,000 ppm of acetic acid after storage at room temperature for at least 12 months following initiation of storage.
11 . A storage stable pharmaceutical composition comprising:
the storage stable sulfated glycosaminoglycan according to claim 1 ; and
a pharmaceutical carrier, said pharmaceutical carrier being mixed with said sulfated glycosaminoglycan.
12 . The storage stable pharmaceutical composition of claim 11 further comprising a pharmaceutically active agent.
13 . The storage stable pharmaceutical composition of claim 12 , wherein said pharmaceutically active agent is selected from the group consisting of pharmaceutically acceptable free bases, salts, esters, ethers, or solvates of antibiotics, anti-infectives, antimycotics agents, steroids, cannabinoids, antihistamines, anti-inflammatory agents, antiparasitic agents, immunomodulators, antisense agents, antiviral agents, treatments for hyper -and hypo skin pigmentation disorders, anti-psoriatic agents, keratolytic agents, DNA synthesis inhibitors, cytotoxic agents, antithyroid agents, monoclonal antibody regulators, TNF alpha antagonists, immunoglobulins, metabolic regulators, antiangiogenic agents, protease inhibitors, anxiolytics, kinase regulators, cell growth regulators, enzymes, prostaglandins, peptides, analgesics, skin moisturizers, astringents, exfoliating agents, agents intended to protect the skin or modify its appearance or improve its rate of healing, and combinations thereof.
14 . The storage stable pharmaceutical composition of claim 11 further comprising:
an additive selected from the group consisting of adjuvants, gelling agents, thickeners, solvents, preservatives, pH modifiers, colorants, perfumes, flavors, propellants, absorbents, adsorbents, antioxidants, antimicrobial preservatives, and combinations thereof.
15 . The storage stable pharmaceutical composition of claim 11 further comprising an additive selected from the group consisting of tocopherol acetate, an aloe derivative, a silicon derivative, a chelating agent, an emulsifier, a polyol, water, and combinations thereof.
16 . The storage stable pharmaceutical composition of claim 11 , wherein said pharmaceutical carrier is an injectable liquid, solution, or emulsion capable of dissolving said sulfated glycosaminoglycan.
17 . The storage stable pharmaceutical composition of claim 11 , wherein the storage stable pharmaceutical composition comprises 0.1 to 25 wt % of said sulfated glycosaminoglycan and 75 to 99 wt % of said carrier.
18 . The storage stable pharmaceutical composition of claim 11 , wherein the storage stable pharmaceutical composition comprises 5 to 16 wt % of said sulfated glycosaminoglycan and 84 to 95 wt % of said carrier.
19 . A storage stable polysulfated glycosaminoglycan, wherein said polysulfated glycosaminoglycan is purified and has an average molecular weight ranging from 3,000 to 15,000 Daltons, wherein said polysulfated glycosaminoglycan maintains a white or off-white color after storage at room temperature for at least 6 months following initiation of storage.
20 . The storage stable polysulfated glycosaminoglycan of claim 9 , wherein said purified polysulfated glycosaminoglycan is prepared by a process comprising filtration and/or precipitation.
21 . The storage stable polysulfated glycosaminoglycan of claim 19 , wherein said purified polysulfated glycosaminoglycan has been purified by precipitation from an alcoholic solvent.
22 . The storage stable polysulfated glycosaminoglycan of claim 21 , wherein said purified polysulfated glycosaminoglycan has been purified by precipitation from methanol.
23 . The storage stable polysulfated glycosaminoglycan of claim 21 , wherein said purified polysulfated glycosaminoglycan has been purified by precipitation from ethanol.
24 . The storage stable polysulfated glycosaminoglycan of claim 9 , wherein said polysulfated glycosaminoglycan maintains a white or off-white color after storage at room temperature for at least 12 months following initiation of storage.
25 . The storage stable polysulfated glycosaminoglycan of claim 19 , wherein said polysulfated glycosaminoglycan is prepared by a process comprising
subjecting a polysulfated glycosaminoglycan starting material containing components below 1,000 Daltons to tangential flow filtration under conditions effective to reduce the amount of components below 1,000 Daltons in the starting material to produce the purified polysulfated glycosaminoglycan having an average molecular weight ranging from 3,000 to 15,000 Daltons.
26 . The storage stable polysulfated glycosaminoglycan of claim 19 , wherein said purified polysulfated glycosaminoglycan is prepared by a process comprising:
subjecting a polysulfated glycosaminoglycan starting material containing components below 3,000 Daltons to tangential flow filtration under conditions effective to reduce the amount of components below 3,000 Daltons in the starting material to produce the purified polysulfated glycosaminoglycan having an average molecular weight ranging from 3,000 to 15,000 Daltons.
27 . The storage stable polysulfated glycosaminoglycan of claim 19 , wherein said purified polysulfated glycosaminoglycan is prepared by a process comprising:
subjecting a polysulfated glycosaminoglycan starting material containing components below 5,000 Daltons to tangential flow filtration under conditions effective to reduce the amount of components below 5,000 Daltons in the starting material to produce the purified polysulfated glycosaminoglycan having an average molecular weight ranging from 3,000 to 15,000 Daltons.
28 . The storage stable polysulfated glycosaminoglycan of claim 19 , wherein said polysulfated glycosaminoglycan maintains a white or off-white color after storage at room temperature for at least 18 months following initiation of storage.
29 . The storage stable polysulfated glycosaminoglycan of claim 19 , wherein said polysulfated glycosaminoglycan maintains a white or off-white color after storage at room temperature for at least 24 months following initiation of storage.
30 . A storage stable pharmaceutical composition comprising:
the storage stable polysulfated glycosaminoglycan according to claim 9 ; and
a pharmaceutical carrier, said pharmaceutical carrier being mixed with said polysulfated glycosaminoglycan.
31 . The storage stable pharmaceutical composition of claim 30 further comprising a pharmaceutically active agent.
32 . The storage stable pharmaceutical composition of claim 31 , wherein said pharmaceutically active agent is selected from the group consisting of pharmaceutically acceptable free bases, salts, esters, ethers, or solvates of antibiotics, anti-infectives, antimycotics agents, steroids, cannabinoids, antihistamines, anti-inflammatory agents, antiparasitic agents, immunomodulators, antisense agents, antiviral agents, treatments for hyper- and hypo skin pigmentation disorders, anti-psoriatic agents, keratolytic agents, DNA synthesis inhibitors, cytotoxic agents, antithyroid agents, monoclonal antibody regulators, TNF alpha antagonists, immunoglobulins, metabolic regulators, antiangiogenic agents, protease inhibitors, anxiolytics, kinase regulators, cell growth regulators, enzymes, prostaglandins, peptides, analgesics, skin moisturizers, astringents, exfoliating agents, agents intended to protect the skin or modify its appearance or improve its rate of healing, and combinations thereof.
33 . The storage stable pharmaceutical composition of claim 30 further comprising:
an additive selected from the group consisting of adjuvants, gelling agents, thickeners, solvents, preservatives, pH modifiers, colorants, perfumes, flavors, propellants, absorbents, adsorbents, antioxidants, antimicrobial preservatives, and combinations thereof.
34 . The storage stable pharmaceutical composition of claim 30 further comprising an additive selected from the group consisting of tocopherol acetate, an aloe derivative, a silicon derivative, a chelating agent, an emulsifier, a polyol, water, and combinations thereof.
35 . The storage stable pharmaceutical composition of claim 30 , wherein said pharmaceutical carrier is an injectable liquid, solution, or emulsion capable of dissolving said purified sulfated glycosaminoglycan.
36 . The storage stable pharmaceutical composition of claim 30 , wherein the storage stable pharmaceutical composition comprises 0.1 to 25 wt % of said polysulfated glycosaminoglycan and 75 to 99 wt % of said carrier.
37 . The storage stable pharmaceutical composition of claim 30 , wherein the storage stable pharmaceutical composition comprises 5 to 16 wt % of said polysulfated glycosaminoglycan and 84 to 95 wt % of said carrier.